We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add BSX Stock to Your Portfolio Now
Read MoreHide Full Article
Boston Scientific’s (BSX - Free Report) growth is backed by its successful expansion of operations across different geographies outside the United States. Its recent acquisitions are expected to drive revenue growth in the long term. Consistent MedSurg market share gain is also highly encouraging. Meanwhile, headwinds such as currency movements raise concern for Boston Scientific.
In the past year, this Zacks Rank #2 (Buy) company’s shares have rallied 63.3% compared with the industry’s 26.5% growth and the S&P 500 composite’s 36.2% gain.
The renowned manufacturer of medical devices and products has a market capitalization of $123.41 billion. BSX has an estimated earnings growth rate of 17.1% for 2024 compared with the industry’s 12.6%. It beat on earnings in each of the trailing four quarters, delivering an average surprise of 7.18%.
Let’s delve deeper.
BSX’s Key Upsides
Continued International Expansion: Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States. Within its international regions, the company is putting additional efforts to expand its foothold in the emerging markets (which are defined as all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada), which hold strong growth potential based on their economic conditions, healthcare sectors and global capabilities.
In the second quarter of 2024, despite geopolitical weaknesses, emerging markets registered sturdy growth, primarily due to continued broad-based momentum across the company’s businesses and investment in these regions. During this period, emerging markets’ net sales grew nearly 19.3% on an operational basis, year over year.
In the second quarter, EMEA sales grew 16.1% year over year on an operational basis with robust performance in Europe within Electrophysiology. In line with this, the company enjoyed continued FARAPULSE account openings and robust utilization as well as growth in structural heart business following positive data presented on ACURATE Neo2. Within Asia Pacific, Boston Scientific is registering strong growth in Japan and China.
Impressive MedSurg Market Share Gain: Boston Scientific is consistently gaining market share within its MedSurg segment. In the second quarter, the company reported strong above-market growth contributions from Biliary franchise, led by high teen growth in AXIOS and the Endoluminal Surgery franchise. Within Urology, Boston Scientific continues to expand its market share globally.
Within Neuromodulation, Boston Scientific’s pain business is consistently gaining traction on the back of its innovative Alpha portfolio. Among the recent developments, the company’s SCS business is witnessing a solid ramp-up on improved U.S. trialing cadence in the second quarter. The company’s Brain and Pain franchises, too, are gaining traction, driven by new product launches in the United States and procedure recovery in Europe.
Image Source: Zacks Investment Research
Impressive Value-Adding Acquisitions: Boston Scientific’s recent acquisitions look impressive, with numerous product additions that have immense potential. This should help boost the top line in the long term.
In September 2024, Boston Scientific closed the acquisition of Silk Road Medical. This acquisition is expected to help the company progress in vascular medicine, where Silk Road has revolutionized stroke prevention and the treatment of carotid artery disease.
BSX’s Key Downsides
Exposure to Currency Movement: Boston Scientific records 40% of its sales from the international market. Therefore, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the past few quarters. In the second quarter, the company had a 160 basis-point impact on revenues from unfavorable currency fluctuations.
BSX’s Estimate Trend
The Zacks Consensus Estimate for 2024 earnings has remained unchanged at $2.40 per share in the past 30 days.
The consensus estimate for 2024 revenues is pegged at $16.26 billion, which indicates a 14.2% increase from the year-ago reported numbers.
TransMedix Group’s earnings are expected to surge 255.8% in 2024. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Shares of the company have risen 197.1% in the past year compared with the industry’s 22.7% growth. TMDX sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
AxoGen, carrying a Zacks Rank of 2 at present, has an earning yield of 94.1% compared with the industry’s 12.3%. Shares of the company have risen 180.6% compared with the industry’s 22.7% growth over the past year. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.46%.
Phibro, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 21% for fiscal 2025 compared with the industry’s 12.6%. In the past year, shares of PAHC have risen 58.7% compared with the industry’s 24.2% growth. PAHC delivered a trailing four-quarter average earnings surprise of 4.10%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Add BSX Stock to Your Portfolio Now
Boston Scientific’s (BSX - Free Report) growth is backed by its successful expansion of operations across different geographies outside the United States. Its recent acquisitions are expected to drive revenue growth in the long term. Consistent MedSurg market share gain is also highly encouraging. Meanwhile, headwinds such as currency movements raise concern for Boston Scientific.
In the past year, this Zacks Rank #2 (Buy) company’s shares have rallied 63.3% compared with the industry’s 26.5% growth and the S&P 500 composite’s 36.2% gain.
The renowned manufacturer of medical devices and products has a market capitalization of $123.41 billion. BSX has an estimated earnings growth rate of 17.1% for 2024 compared with the industry’s 12.6%. It beat on earnings in each of the trailing four quarters, delivering an average surprise of 7.18%.
Let’s delve deeper.
BSX’s Key Upsides
Continued International Expansion: Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States. Within its international regions, the company is putting additional efforts to expand its foothold in the emerging markets (which are defined as all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada), which hold strong growth potential based on their economic conditions, healthcare sectors and global capabilities.
In the second quarter of 2024, despite geopolitical weaknesses, emerging markets registered sturdy growth, primarily due to continued broad-based momentum across the company’s businesses and investment in these regions. During this period, emerging markets’ net sales grew nearly 19.3% on an operational basis, year over year.
In the second quarter, EMEA sales grew 16.1% year over year on an operational basis with robust performance in Europe within Electrophysiology. In line with this, the company enjoyed continued FARAPULSE account openings and robust utilization as well as growth in structural heart business following positive data presented on ACURATE Neo2. Within Asia Pacific, Boston Scientific is registering strong growth in Japan and China.
Impressive MedSurg Market Share Gain: Boston Scientific is consistently gaining market share within its MedSurg segment. In the second quarter, the company reported strong above-market growth contributions from Biliary franchise, led by high teen growth in AXIOS and the Endoluminal Surgery franchise. Within Urology, Boston Scientific continues to expand its market share globally.
Within Neuromodulation, Boston Scientific’s pain business is consistently gaining traction on the back of its innovative Alpha portfolio. Among the recent developments, the company’s SCS business is witnessing a solid ramp-up on improved U.S. trialing cadence in the second quarter. The company’s Brain and Pain franchises, too, are gaining traction, driven by new product launches in the United States and procedure recovery in Europe.
Image Source: Zacks Investment Research
Impressive Value-Adding Acquisitions: Boston Scientific’s recent acquisitions look impressive, with numerous product additions that have immense potential. This should help boost the top line in the long term.
In September 2024, Boston Scientific closed the acquisition of Silk Road Medical. This acquisition is expected to help the company progress in vascular medicine, where Silk Road has revolutionized stroke prevention and the treatment of carotid artery disease.
BSX’s Key Downsides
Exposure to Currency Movement: Boston Scientific records 40% of its sales from the international market. Therefore, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the past few quarters. In the second quarter, the company had a 160 basis-point impact on revenues from unfavorable currency fluctuations.
BSX’s Estimate Trend
The Zacks Consensus Estimate for 2024 earnings has remained unchanged at $2.40 per share in the past 30 days.
The consensus estimate for 2024 revenues is pegged at $16.26 billion, which indicates a 14.2% increase from the year-ago reported numbers.
Other Key Picks
Some other top-ranked stocks in the broader medical space are TransMedix Group (TMDX - Free Report) , AxoGen (AXGN - Free Report) and Phibro Animal Health (PAHC - Free Report) .
TransMedix Group’s earnings are expected to surge 255.8% in 2024. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Shares of the company have risen 197.1% in the past year compared with the industry’s 22.7% growth. TMDX sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
AxoGen, carrying a Zacks Rank of 2 at present, has an earning yield of 94.1% compared with the industry’s 12.3%. Shares of the company have risen 180.6% compared with the industry’s 22.7% growth over the past year. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.46%.
Phibro, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 21% for fiscal 2025 compared with the industry’s 12.6%. In the past year, shares of PAHC have risen 58.7% compared with the industry’s 24.2% growth. PAHC delivered a trailing four-quarter average earnings surprise of 4.10%.